NRT briefing
CVS Pharmacy reaches $315M settlement with Justice Department over controlled substance prescriptions
Based on reporting by Fox Business.
The Brief
CVS has agreed to pay $315 million to resolve Justice Department allegations that it illegally filled prescriptions for opioids and other controlled substances and billed federal health care programs. The settlement resolves a case filed by the federal government in 2024, covering prescriptions filled between October 2013 and December 2025.
The DOJ alleged CVS knowingly filled prescriptions lacking a legitimate medical purpose, including excessive quantities, early refills, dangerous combinations, and prescriptions from "pill mill" prescribers. The company disputed the allegations and did not admit wrongdoing. As part of the agreement, CVS must implement additional safeguards, including a hotline for reporting suspected illegal dispensing and procedures to evaluate prescribers. This follows CVS's 2022 agreement to pay nearly $5 billion over opioid-related claims.
NRT commentary
How We See It
This settlement underscores the ongoing federal effort to hold pharmacies accountable in the opioid crisis. While CVS admits no wrongdoing, the $315 million payment and the DEA-mandated compliance measures signal that the government expects pharmacies to be more than passive order-fillers.
The DOJ's focus on corporate policies that prioritize profits over patient safety is a pointed reminder that business incentives matter. Going forward, pharmacy chains should reassess their internal metrics and compliance programs, not merely to avoid penalties, but to regain public trust.
Watchdogs will need to ensure that these new safeguards are implemented in practice, not just on paper.
Commentary uses AI assistance. What is How We See It? Read about our automated checks or report a correction.